<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31454195</article-id><article-id pub-id-type="pmc">6713362</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0341</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Early Outcomes of Low Postoperative Bleeding after Off-Pump Coronary
Artery Bypass Grafting</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Weitie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Piao</surname><given-names>Hulin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Bo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Tiance</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Dan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Zhicheng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Rihao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6099-5351</contrib-id><name><surname>Liu</surname><given-names>Kexiang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><aff id="aff1">
<label>1</label> Department of Cardiovascular Surgery, 2nd Hospital of Bethune,
Jilin University, Changchun, Jilin, China.</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Kexiang Liu,
https://orcid.org/0000-0001-6099-5351, 2nd Hospital of Jilin University, 218
Ziqiang Street, Nanguan District, Changchun, Jilin, China, Zip Code: 130041.
E-mail: <email>kxliu64@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jul-Aug</season><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2019</year></pub-date><volume>34</volume><issue>4</issue><fpage>412</fpage><lpage>419</lpage><history><date date-type="received"><day>31</day><month>8</month><year>2018</year></date><date date-type="accepted"><day>24</day><month>11</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To investigate whether low bleeding influences the early outcomes after
off-pump coronary artery bypass grafting (CABG).</p></sec><sec><title>Methods</title><p>Retrospective analysis of ischemic heart disease patients who underwent
off-pump CABG from January 2013 to December 2017. Patients were divided into
low-bleeding group (n=659) and bleeding group (n=270), according to total
drainage from chest tube during the first postoperative 12 hours. Clinical
material and early outcomes were compared between the groups.</p></sec><sec><title>Results</title><p>Baseline was similar in the two groups. Operation time was 270&#x000b1;51 min
in the low-bleeding group and 235&#x000b1;46 min in the bleeding group
(<italic>P</italic>&#x0003c;0.0001). The low-bleeding group presented smaller
drainage during the first 12 h (237&#x000b1;47 ml) and shorter mechanical
ventilation time (6.86&#x000b1;3.78 h) than the bleeding group
(557&#x000b1;169 ml and 10.66&#x000b1;5.19 h, respectively)
(<italic>P</italic>&#x0003c;0.0001). Hemodynamic status was more stable in
the low-bleeding group (<italic>P</italic>&#x0003c;0.0001) and usage rate of more
than two vasoactive agents in this group was lower than in the bleeding
group (<italic>P</italic>&#x0003c;0.0001). Number of distal anastomosis,
reoperation for bleeding, suddenly increase in chest tube output, intensive
care unit (ICU) stay, hospital stay, and other early outcomes had no
statistical significance between the groups
(<italic>P</italic>&#x0003e;0.05).</p></sec><sec><title>Conclusion</title><p>Postoperative bleeding &#x0003c; 300 ml/12 h in off-pump CABG patients did not
require blood product transfusion and reoperation and that would contribute
to reduction in mechanical ventilation time and maintaining hemodynamic
stability. Bleeding &#x0003c; 800 ml during the first postoperative 12 h did not
increase infection rates and ICU length of stay.</p></sec></abstract><kwd-group><kwd>Off-Pump Coronary Artery Bypass</kwd><kwd>Respiration, Artificial</kwd><kwd>Coronary Artery Disease</kwd><kwd>Reoperation</kwd><kwd>Hemodynamics</kwd></kwd-group></article-meta></front><body><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="42%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="42%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th><th align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AKI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Acute kidney injury</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LCOS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Low cardiac output
syndrome</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BMI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Body mass index</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LIMA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left internal mammary
artery</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
ejection fraction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CAD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery
disease</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Myocardial
infarction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">COPD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Chronic obstructive
pulmonary disease</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NYHA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= New York Heart
Association</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary
bypass</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PCI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Percutaneous coronary
intervention</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CRD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Chronic renal
dysfunction</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RBC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Red blood cell</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CRF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Chronic renal
failure</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RITA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Right internal thoracic
artery</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">DM</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Standard deviation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ECG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Electrocardiogram</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SPSS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Statistical Package for
the Social Sciences</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">GFR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Glomerular filtration
rate</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SVG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Saphenous vein
graft</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IABP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intra-aortic balloon
pump</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">UDPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Universal definition of
perioperative bleeding</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ICU</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intensive care unit</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>With aspirin being recommended to be administered to coronary artery bypass grafting
(CABG) patients preoperatively since 2010, the risk of cardiovascular events
significantly decreased<sup>[<xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r3" ref-type="bibr">3</xref>]</sup>. However, it also increased hemorrhage-related
risks, surgical re-explorations, the volume of red blood cell (RBC)
transfusions<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>, and in-hospital mortality<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>]</sup>. Numerous studies had
reported the effects of massive bleeding, surgical re-explorations, or blood product
transfusions on surgical mortality<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>. However, few studies investigated the effects
of low postoperative bleeding on the hemodynamic status. Undoubtedly, less bleeding
has some advantage, and it would avoid blood transfusions and decrease risk of
reoperations. Besides, low postoperative bleeding after cardiac surgery had also
shown to reduce the incidence of hemodynamic instability and to promote recovery
after surgery. In order to evaluate the potential effects of low postoperative
bleeding in patients undergoing off-pump CABG, we performed this retrospective
cohort study to analyze the association between low postoperative bleeding and
perioperative outcomes.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This is a retrospective study and it was approved by the Ethics Committee of the
Second Hospital of Jilin University. Consent form was obtained from every patient
before discharge. All operations were performed by the same surgeon (K.L.). A total
of 1052 patients underwent surgical revascularization from January 2013 to December
2017. Inclusion criteria were: 1) patients with ischemic heart disease who met
surgical revascularization criterion; 2) off-pump CABG without blood product
transfusions and postoperative reoperations for bleeding; 3) no other cardiac
diseases which required concomitant interventions, such as ventricular septal
defect, medium to severe mitral regurgitation, and left ventricle aneurysm; 4)
patients who regularly took acetylsalicylic acid until
operation<sup>[<xref rid="r8" ref-type="bibr">8</xref>-<xref rid="r10" ref-type="bibr">10</xref>]</sup>; 5) patients without other system diseases,
especially hematological diseases; and 6) chest tube drainage during the first 12 h
less than 800 ml (insignificant and mild), according to the universal definition of
perioperative bleeding (UDPB) categories in adult cardiac
surgery<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. Therefore, a total of 929 patients were enrolled
in this study. All patients were further divided into two subgroups according to
their postoperative bleeding volume: low-bleeding group (&#x0003c;300 ml/12 h) and
bleeding group (300-800 ml/12 h). All patients were followed up until the 6th
postoperative month after discharge.</p><sec><title>Surgical Procedures</title><p>All surgery was performed through a median sternotomy. Left/right internal
mammary artery and saphenous vein grafts (SVG) were harvested at the same time
using &#x0201c;no-touch&#x0201d; technique. Deep pericardial sutures were performed after
incision in the pericardium. Heparin was administered (1 mg/kg). The Medtronic
Octopus apical suction positioning device and Starfish apical suction
positioning device (Medtronic, Inc., Minneapolis, Minnesota, USA) were used for
stabilization. Surgical revascularization was always started from the left
internal mammary artery (LIMA) to the left anterior descending coronary
territory. Then, sequential technique was employed to the right coronary artery,
left circumflex and diagonal artery by one SVG. The quality of the anastomosis
was assessed by transit-time flow probe (Medistim Butterfly Flow Meter, Oslo,
Norway). All the target vessels were exposed and controlled with silastic sling.
A CO<sub>2</sub>-blower mister device was utilized to achieve the visualization
of the operative field. After anastomosis, heparin was neutralized with 50 mg of
protamine and 1 g of calcium gluconate. A cell salvage device was used in all
surgeries and the salvaged blood was reinfused into the patient during the
operation. To avoid hypothermia-induced arrhythmia, central temperature was
maintained above 36 &#x000ba;C.</p><p>Baseline clinical data included age, sex, body mass index, smoking, New York
Heart Association (NYHA) class, previous percutaneous coronary intervention
(PCI), diabetes mellitus (DM), chronic renal dysfunction (CRD), previous
myocardial infarction (MI), recent MI, congestive heart failure, hypertension,
hyperkinemia, chronic obstructive pulmonary disease (COPD), stroke, prior
cerebrovascular accident, abnormal motion of the segmental cardiac wall, left
ventricular ejection fraction (LVEF), anatomical severity of coronary artery
disease (CAD), hemoglobin, PO<sub>2</sub>, activated partial thromboplastin
time, international normalized ratio, partial thrombin time, thrombin time,
fibrinogen, and EuroSCORE. Operative data included operation time, number of
distal anastomosis, the use of SVG, LIMA and right internal thoracic artery
(RITA), the use of composite graft, and prophylactic intra-aortic balloon pump
(IABP) support. Postoperative data included surgical mortality, drainage during
the first 12 h, re-explorations for bleeding, duration of mechanical
ventilation, prolonged postoperative ventilatory support (longer than 24 hours),
the lengths of intensive care unit (ICU) stay and hospital stay, ventricular
arrhythmia, low cardiac output syndrome (LCOS), sudden increase in chest tube
output, tamponade, stroke, MI, hemodynamic instabilities (systolic pressure &#x0003c;
90 mmHg and heart rate &#x0003e; 120 bpm), and application of more than two
vasoactive agents. Bivariate analyses were used to examine differences in
baseline characteristics between the two groups.</p><p>The primary end point of this study was overall death, including in-hospital
mortality and death occurring within 30 days after surgery. The secondary end
points were major postoperative morbidities, such as LCOS, new onset of acute
MI, and other cardiac-related complications. Follow-up information was obtained
by outpatient clinic visit or telephone calls. All patients underwent
echocardiographic reexamination at the 6<sup>th</sup> postoperative month.</p></sec><sec><title>Definitions</title><p>Surgical mortality was defined as in-hospital death or death occurring within 30
days of the surgery. The secondary end points were other operation-related
complications. Resternotomy for bleeding was defined as reoperation to control
bleeding within 36 hours following the initial surgery. Postoperative MI was
defined by the appearance of new Q waves in two or more contiguous leads on the
electrocardiogram (ECG). Postoperative LCOS was defined as the requirement for
IABP and/or inotropic support for longer than 30 mins. Postoperative atrial or
ventricular arrhythmia was defined as any episode of atrial/ventricular
fibrillation, which was recognized by the monitoring system on a rhythm strip or
the 12-lead ECG. Postoperative respiratory failure was defined as duration of
mechanical ventilation longer than 72 hours or in-hospital re-intubation.
Postoperative pneumonia was a positive result in a sputum culture requiring
anti-infective treatment or chest X-ray diagnosis of pneumonia following cardiac
surgery. Stroke was defined as new onset of permanent neurological events
lasting over 24 hours. Deep sternal wound infection was bone-related, any
drainage of purulent secretions from the sternotomy wound, and instability of
the sternum. Acute kidney injury (AKI) was defined and classified according to
the criteria proposed by the Acute Kidney Injury Network. Chronic renal failure
(CRF) was diagnosed in patients whose glomerular filtration rate (GFR) declined
to 15-20 ml/minute, with severe symptoms related to uraemia, requiring renal
replacement therapy. Blood loss (measured by chest tube drainage) was recorded
at or close to 12 h after surgery. More than two vasoactive agents indicated
that dopamine and glyceryl trinitrate were routinely used during and after
operation, while adrenaline or norepinephrine were added if the blood pressure
was &#x0003c; 90 mmHg, despite dopamine and glyceryl trinitrate infusions.</p></sec><sec><title>Statistics</title><p>Continuous data were expressed as mean &#x000b1; standard deviation (SD),
categorical variables were expressed as numbers (percentages). Normally and
non-normally distributed continuous variables were compared using Student&#x02019;s
t-test and Mann-Whitney U test, respectively. The Fisher&#x02019;s exact test or the
chi-square test was used to compare categorical variables.
<italic>P</italic>-value &#x0003c; 0.05 was considered statistically significant. All
statistical analyses were carried out by the Statistical Package for the Social
Sciences (SPSS) software (version 19.0).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Study Population</title><p>There were 659 patients in the low-bleeding group and 270 patients in the
bleeding group. The mean age was 60.61&#x000b1;8.23 and 60.53&#x000b1;8.32 years
in the low-bleeding group and the bleeding group, respectively. There were no
significant differences in hemoglobin, PO<sub>2</sub>, activated partial
thromboplastin time, international normalized ratio, partial thrombin time,
thrombin time, and fibrinogen. More details of the baseline characteristics were
shown in <xref rid="t1" ref-type="table">Table 1</xref>. There were no
significant differences in age, gender, obesity, smoking, NYHA class III-IV,
previous MI, previous PCI, hypertension, DM, CRF, recent MI, congestive heart
failure, hyperlipemia, COPD, prior cerebrovascular accident, abnormal motion of
the segmental cardiac wall, LVEF, and EuroSCORE between the two groups.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patients' baseline and procedural characteristics after matching.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Low-bleeding group (N=659)</th><th align="center" rowspan="1" colspan="1">Bleeding group (N=270)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years old)</td><td align="center" rowspan="1" colspan="1">60.61&#x000b1;8.23</td><td align="center" rowspan="1" colspan="1">60.53&#x000b1;8.32</td><td align="center" rowspan="1" colspan="1">0.8934</td></tr><tr><td align="left" rowspan="1" colspan="1">Males</td><td align="center" rowspan="1" colspan="1">425 (64.49%)</td><td align="center" rowspan="1" colspan="1">178 (65.93%)</td><td align="center" rowspan="1" colspan="1">0.6775</td></tr><tr><td align="left" rowspan="1" colspan="1">Obesity (BMI &#x0003e; 30 kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">345 (52.35%)</td><td align="center" rowspan="1" colspan="1">142 (52.59%)</td><td align="center" rowspan="1" colspan="1">0.9469</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="center" rowspan="1" colspan="1">311 (47.19%)</td><td align="center" rowspan="1" colspan="1">125 (46.30%)</td><td align="center" rowspan="1" colspan="1">0.8037</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA class III-IV</td><td align="center" rowspan="1" colspan="1">405 (61.46%)</td><td align="center" rowspan="1" colspan="1">162 (60.00%)</td><td align="center" rowspan="1" colspan="1">0.6793</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous myocardial infarction (MI)</td><td align="center" rowspan="1" colspan="1">331 (50.23%)</td><td align="center" rowspan="1" colspan="1">142 (52.59%)</td><td align="center" rowspan="1" colspan="1">0.5127</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous PCI</td><td align="center" rowspan="1" colspan="1">67 (10.17%)</td><td align="center" rowspan="1" colspan="1">28 (10.37%)</td><td align="center" rowspan="1" colspan="1">0.9260</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">336 (50.99%)</td><td align="center" rowspan="1" colspan="1">141 (48.51%)</td><td align="center" rowspan="1" colspan="1">0.7322</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">216 (32.78%)</td><td align="center" rowspan="1" colspan="1">92 (34.07%)</td><td align="center" rowspan="1" colspan="1">0.7030</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic renal dysfunction</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Recent MI</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Congestive heart failure</td><td align="center" rowspan="1" colspan="1">54 (8.19%)</td><td align="center" rowspan="1" colspan="1">18 (6.67%)</td><td align="center" rowspan="1" colspan="1">0.4292</td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperlipemia</td><td align="center" rowspan="1" colspan="1">435 (66.01%)</td><td align="center" rowspan="1" colspan="1">177 (65.56%)</td><td align="center" rowspan="1" colspan="1">0.8947</td></tr><tr><td align="left" rowspan="1" colspan="1">COPD</td><td align="center" rowspan="1" colspan="1">45 (6.83%)</td><td align="center" rowspan="1" colspan="1">19 (7.04%)</td><td align="center" rowspan="1" colspan="1">0.9093</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior cerebrovascular accident</td><td align="center" rowspan="1" colspan="1">188 (28.53%)</td><td align="center" rowspan="1" colspan="1">69 (25.56%)</td><td align="center" rowspan="1" colspan="1">0.4698</td></tr><tr><td align="left" rowspan="1" colspan="1">Abnormal motion of the segmental cardiac wall</td><td align="center" rowspan="1" colspan="1">364 (55.24%)</td><td align="center" rowspan="1" colspan="1">138 (51.11%)</td><td align="center" rowspan="1" colspan="1">0.2521</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEF</td><td align="center" rowspan="1" colspan="1">56.91&#x000b1;4.49</td><td align="center" rowspan="1" colspan="1">56.41&#x000b1;4.59</td><td align="center" rowspan="1" colspan="1">0.1261</td></tr><tr><td align="left" rowspan="1" colspan="1">Extent of CAD</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Left main stem disease</td><td align="center" rowspan="1" colspan="1">191 (28.98%)</td><td align="center" rowspan="1" colspan="1">78 (28.89%)</td><td align="center" rowspan="1" colspan="1">0.9770</td></tr><tr><td align="left" rowspan="1" colspan="1">Three vessels</td><td align="center" rowspan="1" colspan="1">580 (88.01%)</td><td align="center" rowspan="1" colspan="1">241 (89.26%)</td><td align="center" rowspan="1" colspan="1">0.5903</td></tr><tr><td align="left" rowspan="1" colspan="1">Two vessels</td><td align="center" rowspan="1" colspan="1">43 (6.52%)</td><td align="center" rowspan="1" colspan="1">17 (6.30%)</td><td align="center" rowspan="1" colspan="1">0.8975</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin (mg/l)</td><td align="center" rowspan="1" colspan="1">129.27&#x000b1;18.81</td><td align="center" rowspan="1" colspan="1">128.99&#x000b1;19.01</td><td align="center" rowspan="1" colspan="1">0.8373</td></tr><tr><td align="left" rowspan="1" colspan="1">PO<sub>2</sub></td><td align="center" rowspan="1" colspan="1">83.21&#x000b1;11.23</td><td align="center" rowspan="1" colspan="1">82.19&#x000b1;12.44</td><td align="center" rowspan="1" colspan="1">0.2237</td></tr><tr><td align="left" rowspan="1" colspan="1">Activated partial thromboplastin time (s)</td><td align="center" rowspan="1" colspan="1">11.18&#x000b1;2.24</td><td align="center" rowspan="1" colspan="1">11.19&#x000b1;2.33</td><td align="center" rowspan="1" colspan="1">0.9513</td></tr><tr><td align="left" rowspan="1" colspan="1">International normalized ratio</td><td align="center" rowspan="1" colspan="1">0.99&#x000b1;0.12</td><td align="center" rowspan="1" colspan="1">0.98&#x000b1;0.11</td><td align="center" rowspan="1" colspan="1">0.2379</td></tr><tr><td align="left" rowspan="1" colspan="1">Partial thrombin time (s)</td><td align="center" rowspan="1" colspan="1">35.12&#x000b1;8.68</td><td align="center" rowspan="1" colspan="1">35.11&#x000b1;8.71</td><td align="center" rowspan="1" colspan="1">0.9873</td></tr><tr><td align="left" rowspan="1" colspan="1">Thrombin time (s)</td><td align="center" rowspan="1" colspan="1">14.33&#x000b1;3.57</td><td align="center" rowspan="1" colspan="1">14.29&#x000b1;3.54</td><td align="center" rowspan="1" colspan="1">0.8765</td></tr><tr><td align="left" rowspan="1" colspan="1">Fibrinogen (g/l)</td><td align="center" rowspan="1" colspan="1">3.68&#x000b1;0.99</td><td align="center" rowspan="1" colspan="1">3.69&#x000b1;1.01</td><td align="center" rowspan="1" colspan="1">0.8895</td></tr><tr><td align="left" rowspan="1" colspan="1">Logistic EuroSCORE</td><td align="center" rowspan="1" colspan="1">6.12&#x000b1;2.01</td><td align="center" rowspan="1" colspan="1">6.08&#x000b1;1.97</td><td align="center" rowspan="1" colspan="1">0.7818</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>BMI=body mass index; CAD=coronary artery disease; COPD=chronic
obstructive pulmonary disease; LVEF=left ventricular ejection
fraction; NYHA=New York Heart Association; PCI=percutaneous coronary
intervention</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Intra-operative Data</title><p>The operation time was 270&#x000b1;51 min in the low-bleeding group and
235&#x000b1;46 min in the bleeding group (<italic>P</italic>&#x0003c;0.0001). The
number of distal anastomosis (ranging from two to five) was 3.37&#x000b1;0.79 in
the low-bleeding group and 3.36&#x000b1;0.80 in the bleeding group. Internal
mammary artery was used in all patients, while the number of SVG was 657 in the
low-bleeding group and 269 in the bleeding group. Postoperative hemoglobin was
111.42&#x000b1;21.56 and 112.31&#x000b1;22.07 in the low-bleeding group and the
bleeding group, respectively. Prophylactic IABP support was used in four (0.61%)
patients in the low-bleeding group and in three (1.11%) in the bleeding group
(<italic>P</italic>=0.4198). The details are shown in <xref rid="t2" ref-type="table">Table 2</xref>.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Perioperative characteristics after matching.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Low-bleeding group (N=659)</th><th align="center" rowspan="1" colspan="1">Bleeding group (N=270)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Operation time (min)</td><td align="center" rowspan="1" colspan="1">270&#x000b1;51</td><td align="center" rowspan="1" colspan="1">235&#x000b1;46</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">No. of distal anastomosis</td><td align="center" rowspan="1" colspan="1">3.37&#x000b1;0.79</td><td align="center" rowspan="1" colspan="1">3.36&#x000b1;0.80</td><td align="center" rowspan="1" colspan="1">0.8615</td></tr><tr><td align="left" rowspan="1" colspan="1">SVG use</td><td align="center" rowspan="1" colspan="1">657(99.70%)</td><td align="center" rowspan="1" colspan="1">269(99.62%)</td><td align="center" rowspan="1" colspan="1">0.8704</td></tr><tr><td align="left" rowspan="1" colspan="1">LIMA use</td><td align="center" rowspan="1" colspan="1">657(99.70%)</td><td align="center" rowspan="1" colspan="1">269(99.62%)</td><td align="center" rowspan="1" colspan="1">0.8704</td></tr><tr><td align="left" rowspan="1" colspan="1">RITA use</td><td align="center" rowspan="1" colspan="1">2(0.30%)</td><td align="center" rowspan="1" colspan="1">1(0.38%)</td><td align="center" rowspan="1" colspan="1">0.4353</td></tr><tr><td align="left" rowspan="1" colspan="1">Composite grafting</td><td align="center" rowspan="1" colspan="1">657(99.70%)</td><td align="center" rowspan="1" colspan="1">269(99.62%)</td><td align="center" rowspan="1" colspan="1">0.8704</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin after operation (mg/l)</td><td align="center" rowspan="1" colspan="1">111.42&#x000b1;21.56</td><td align="center" rowspan="1" colspan="1">112.31&#x000b1;22.07</td><td align="center" rowspan="1" colspan="1">0.5706</td></tr><tr><td align="left" rowspan="1" colspan="1">Prophylactic IABP support</td><td align="center" rowspan="1" colspan="1">4(0.61%)</td><td align="center" rowspan="1" colspan="1">3(1.11%)</td><td align="center" rowspan="1" colspan="1">0.4198</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>IABP=intra-aortic balloon pump; LIMA=left internal mammary artery;
RITA=right internal thoracic artery; SVG=saphenous vein graft</p></fn></table-wrap-foot></table-wrap><p>Drainage (<xref ref-type="fig" rid="f1">Figure 1</xref>) during the first 12 h in
the low-bleeding group (237&#x000b1;47 ml) was significantly lower than in the
bleeding group (557&#x000b1;169 ml) (<italic>P</italic>&#x0003c;0.0001). Time of
mechanical ventilation (6.86&#x000b1;3.78 h) in the low-bleeding group was also
significantly shorter than in the bleeding group (10.66&#x000b1;5.19 h).
Hemodynamic status (<xref ref-type="fig" rid="f2">Figure 2</xref>) (including
systolic pressure and heart rate) was more stable in the low-bleeding group
(<italic>P</italic>&#x0003c;0.0001) and the usage rate of more than two
vasoactive agents in the low-bleeding group was also lower than in the bleeding
group (<italic>P</italic>&#x0003c;0.0001). There were no significant differences in
resternotomy for bleeding, sudden increase in chest tube output, ICU stay,
hospital stay, hemoglobin, ventricular arrhythmia, LCOS, MI, prolonged
postoperative ventilatory support longer than 24 hours, respiratory failure,
pneumonia, tamponade, deep surgical sternal wound, hemoglobin at the first
postoperative 12 hours, and LVEF before discharge. More details of the
postoperative data were shown in <xref rid="t3" ref-type="table">Table 3</xref>.
All discharged patients were followed up until the 6th postoperative month, with
no death occurring within six months in the two groups.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Patient&#x02019;s bleeding of every hour after transfer to intensive care
unit (ICU).</p></caption><graphic xlink:href="rbccv-34-04-0412-g01"/></fig>
</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Hemodynamic status including systolic pressure and heart rate.
Extubation happened when the systolic pressure and heart rate were
simultaneously stable. ICU = intensive care unit</p></caption><graphic xlink:href="rbccv-34-04-0412-g02"/></fig>
</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Postoperative data.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Low-bleeding group (N=659)</th><th align="center" rowspan="1" colspan="1">Bleeding group (N=270)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>In-hospital</italic></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Surgical mortality</td><td align="center" rowspan="1" colspan="1">4(0.61 %)</td><td align="center" rowspan="1" colspan="1">2(0.74 %)</td><td align="center" rowspan="1" colspan="1">0.817</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Resternotomy for bleeding</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Duration of mechanical ventilation (hour)</td><td align="center" rowspan="1" colspan="1">6.86&#x000b1;3.78</td><td align="center" rowspan="1" colspan="1">10.66&#x000b1;5.19</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Prolonged postoperative ventilatory support
&#x0003e; 24 hours</td><td align="center" rowspan="1" colspan="1">7(1.06%)</td><td align="center" rowspan="1" colspan="1">3(1.11%)</td><td align="center" rowspan="1" colspan="1">0.948</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;ICU stay (days)</td><td align="center" rowspan="1" colspan="1">2.49&#x000b1;0.37</td><td align="center" rowspan="1" colspan="1">2.55&#x000b1;0.54</td><td align="center" rowspan="1" colspan="1">0.052</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hospital stay (days)</td><td align="center" rowspan="1" colspan="1">8.45&#x000b1;0.41</td><td align="center" rowspan="1" colspan="1">8.47&#x000b1;0.39</td><td align="center" rowspan="1" colspan="1">0.494</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Ventricular arrhythmia</td><td align="center" rowspan="1" colspan="1">5 (0.76 %)</td><td align="center" rowspan="1" colspan="1">2(0.74 %)</td><td align="center" rowspan="1" colspan="1">0.977</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Low output syndrome</td><td align="center" rowspan="1" colspan="1">3 (0.46 %)</td><td align="center" rowspan="1" colspan="1">1(0.37 %)</td><td align="center" rowspan="1" colspan="1">0.858</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Drainage during the first 12 h (ml)</td><td align="center" rowspan="1" colspan="1">237&#x000b1;47</td><td align="center" rowspan="1" colspan="1">557&#x000b1;169</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Sudden increase in chest tube output</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Tamponade</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hemoglobin at the first 12 h after
operation</td><td align="center" rowspan="1" colspan="1">103.25&#x000b1;18.89</td><td align="center" rowspan="1" colspan="1">102.97&#x000b1;17.79</td><td align="center" rowspan="1" colspan="1">0.835</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;PO<sub>2</sub></td><td align="center" rowspan="1" colspan="1">119.22&#x000b1;21.56</td><td align="center" rowspan="1" colspan="1">118.89&#x000b1;22.71</td><td align="center" rowspan="1" colspan="1">0.835</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Stroke</td><td align="center" rowspan="1" colspan="1">3 (0.46 %)</td><td align="center" rowspan="1" colspan="1">1(0.37 %)</td><td align="center" rowspan="1" colspan="1">0.858</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Myocardial infarction</td><td align="center" rowspan="1" colspan="1">5 (0.76 %)</td><td align="center" rowspan="1" colspan="1">2(0.74 %)</td><td align="center" rowspan="1" colspan="1">0.977</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Urine of the first 12 h (ml)</td><td align="center" rowspan="1" colspan="1">2765&#x000b1;387</td><td align="center" rowspan="1" colspan="1">2801&#x000b1;399</td><td align="center" rowspan="1" colspan="1">0.202</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Renal dysfunction</td><td align="center" rowspan="1" colspan="1">3 (0.46 %)</td><td align="center" rowspan="1" colspan="1">1(0.37 %)</td><td align="center" rowspan="1" colspan="1">0.858</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Hemodynamic status</italic></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Systolic pressure &#x0003c; 90 mmhg</td><td align="center" rowspan="1" colspan="1">85 (12.89 %)</td><td align="center" rowspan="1" colspan="1">82(30.37 %)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Sinus rhythm rate &#x0003e; 120</td><td align="center" rowspan="1" colspan="1">155 (23.52 %)</td><td align="center" rowspan="1" colspan="1">102(37.78 %)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;More than two vasoactive agents</td><td align="center" rowspan="1" colspan="1">125 (18.97 %)</td><td align="center" rowspan="1" colspan="1">69(25.56 %)</td><td align="center" rowspan="1" colspan="1">0.025</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>For patients with CAD, aspirin had been proved to reduce MI, stroke, and overall
mortality<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. In addition, the continuous usage of aspirin has
been proved to be effective in protecting the graft from
thrombosis<sup>[<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref>]</sup>. So, it had been recommended to be administered
preoperatively. However, the antithrombotic medications also increased bleeding
risks, including the need for blood transfusions and surgical re-explorations for
postoperative bleeding, during and after cardiac surgery<sup>[<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r16" ref-type="bibr">16</xref>]</sup>. Bleeding has always
been a significant problem in cardiac surgery. Massive bleeding would lead to more
blood transfusions and increase chances of re-explorations, which added the
perioperative mortality risk. Even at some circumstances in which bleeding did not
require blood transfusions or surgical re-explorations, it would still affect the
patients&#x02019; postoperative hemodynamic status, which would result in blood pressure
fluctuations and organ malperfusion. Indeed, every patient would experience a
certain degree of postoperative bleeding, which was related to surgical damage to
blood vessels and worsened by hemostatic mechanisms. The widely use of preoperative
antithrombotic and anticoagulation medications was also an important factor, leading
to impaired coagulant balance. In order to reduce postoperative bleeding,
traditional practice had typically involved cessations of oral aspirin for up to
7-10 days before cardiac surgery in low-risk patients<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. However, for some
patients with severe CAD, the benefits of receiving aspirin outweigh the risk of
postoperative bleeding. Therefore, more and more patients continued antiplatelet
agents before a scheduled off-pump CABG. Another factor resulting in massive
postoperative bleeding was hemostasis technology. Perfect anastomosis was easy for
hemostasis and would contribute to less bleeding. Furthermore, it was affected by
the worsened coagulant mechanisms. But the impaired hemostasis mechanisms
preoperatively caused by using antithrombotic medication did not mean we could
perform hemostasis careless. Instead, it called for higher requirements on
hemostasis for these patients, which was an effective method to reduce bleeding
after operation.</p><p>Normally, cardiac surgery patients experience postoperative bleeding of 400-700 ml
approximately. Mortality was influenced by bleeding partly because it had negative
effects on hemodynamics, blood product transfusions, or re-explorations. Transfusion
of blood products had been reported to increase mortality and incidence of
complications, such as renal failure and postoperative
infections<sup>[<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r18" ref-type="bibr">18</xref>]</sup>. Although RBC transfusions could correct the anemia
caused by surgical bleeding, transfusions still increased the complications, even if
the patients received only one unit of blood<sup>[<xref rid="r19" ref-type="bibr">19</xref>,<xref rid="r20" ref-type="bibr">20</xref>]</sup>. Other studies reported that re-explorations
would also increase in-hospital mortality and risk of renal failure, as well as
prolong ventilatory support and increase resource utilization<sup>[<xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r22" ref-type="bibr">22</xref>]</sup>. The relationship
between postoperative bleeding and mortality was investigated through blood product
transfusion or re-exploration, because of the shortage of a precise definition of
bleeding. However, blood transfusions and re-explorations didn&#x02019;t always happen, as
sometimes low bleeding after operation would not require blood product transfusion
or re-exploration. So, the effects of postoperative low bleeding haven&#x02019;t been
reported. Therefore, we aimed to evaluate the effects on the hemodynamic status and
the early outcomes of low bleeding on patients with off-pump CABG, which required no
blood product transfusion or re-explorations. To the authors&#x02019; knowledge, this is the
first study that examines the association between low blood loss and clinical
outcomes.</p><p>However, we also came across the question that at what cut-off point bleeding becomes
clinically significant. It must be calculated with a precise definition of bleeding.
According to the recent definition<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup> for perioperative bleeding, which used multiple
clinically relevant parameters to create a simple five-class system (insignificant,
mild, moderate, severe, or massive) to classify perioperative bleeding, we could
take the bleeding as an outcome measure. That research showed that bleeding less
than 800 ml would not require blood product transfusions or re-explorations, which
meant that the influence of blood product transfusion or re-exploration on mortality
could be avoided. Moreover, another study<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup> showed that there was no significance
in outcomes with bleeding between 150-300 ml during the first 12 hours. So, for the
off-pump CABG patients in our study, postoperative bleedings of 800 ml/12 h and 300
ml/12 h were adopted, with bleeding less than 300 ml as low-bleeding group and
bleeding 300-800ml as bleeding group. To avoid the influence of cardiopulmonary
bypass (CPB) on renal failure and survival rate, we only included off-pump CABG
patients, without the CPB assist. So, in this study, blood transfusion was basically
the only variable influencing postoperative outcomes.</p><p>In our study, the hemodynamic status was more stable in the low-bleeding group.
During the first 12 hours, the incidence of low blood pressure in the low-bleeding
group was less significant than in the bleeding group, especially when comparing
systolic pressure &#x0003c; 90 mmHg. The low blood pressure may be caused by the blood
loss, leading to the rise of the heart rate as a reflection of low blood pressure.
Low blood pressure and fast heart rate must be dealt with supplementary volume
and/or rise of the positive vasoactive agents or the addition of another positive
vasoactive agent, such as adrenaline and/or norepinephrine. Our study presented that
low bleeding in the chest tube drainage would contribute to the hemodynamic status
and reduce the usage of positive vasoactive agents.</p><p>Another influence of low blood drainage was the duration of mechanical ventilation.
The tube drainage in the first several hours always ranged between 50-100 ml and
slowly decreased as the time went by (<xref ref-type="fig" rid="f1">Figure
1</xref>). The extubation happened in the first several hours after the patient
returned to ICU. So, the hemodynamic status in the first several hours was important
for extubation. In the bleeding group, bleeding during the first several hours
always increased the chances of low blood pressure and fast heart rate (<xref ref-type="fig" rid="f2">Figure 2</xref>), the instable hemodynamic status would
make the doctors to be more careful about the decision of extubation, and this was
the possible reason to the longer duration of mechanical ventilation in the bleeding
group than in the low-bleeding group. However, the hypovolemia caused by slow blood
loss was easy to observe and treat, so the instable hemodynamic status always lasted
for a relatively short period, and the visceral organs were not influenced by the
blood pressure fluctuations because of their self-regulation.</p><p>The published study<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup> showed that major bleeding requiring RBC
transfusion would increase infection rates and ICU length of stay. In our study,
both groups didn&#x02019;t require blood product transfusions, despite the bleeding group
lost more blood than the low-bleeding group. So, our research also demonstrated that
bleeding less than 800 ml during the first 12 h did not increase infection rates.
The length of ICU stay and hospital stay between the two groups had no significant
difference. The possible reason was that the postoperative bleeding was gradually
reduced after 12 hours and that the drainage of the chest tube in every hour was
between 5-10 ml, which had little influence on hemodynamic status.</p><sec><title>Limitations</title><p>This study presents several limitations. Firstly, it was a retrospective
observational study based on a single center with a relatively small sample
size, which may influence the generalizability of the results. Secondly,
postoperative bleeding in this study only included the amount of the chest tube
drainage. And the intraoperative blood loss was not included in this study,
which may produce biased results. Thirdly, the influence of a longer operation
time under anesthetic state of the low-bleeding group on postoperative
hemodynamic stability and injury of viscera organs were not definite. Finally,
the midterm and long-term clinical outcomes need further investigations.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>In summary, our study demonstrated that postoperative bleeding less than 300 ml/12 h
in off-pump CABG patients did not require blood product transfusions and
reoperations and that would benefit the extubation and hemodynamic stability.
Besides, our study also showed that bleeding less than 800 ml during the first 12 h
did not increase infection rates and length of ICU stay. Further research with
larger sample is needed to validate these results.</p><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">WW</td><td align="left" valign="top" rowspan="1" colspan="1">Conceived the study, participated in its
design and coordination, and helped to draft the manuscript; final
approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">YW</td><td align="left" valign="top" rowspan="1" colspan="1">Conceived the study, participated in its
design and coordination, and helped to draft the manuscript; final
approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HP</td><td align="left" valign="top" rowspan="1" colspan="1">Conceived the study, participated in its
design and coordination, and helped to draft the manuscript; final
approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BL</td><td align="left" valign="top" rowspan="1" colspan="1">Conceived the study, participated in its
design and coordination, and helped to draft the manuscript; final
approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TW</td><td align="left" valign="top" rowspan="1" colspan="1">Conceived the study, participated in its
design and coordination, and helped to draft the manuscript; final
approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DL</td><td align="left" valign="top" rowspan="1" colspan="1">Conceived the study, participated in its
design and coordination, and helped to draft the manuscript; final
approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ZZ</td><td align="left" valign="top" rowspan="1" colspan="1">Conceived the study, participated in its
design and coordination, and helped to draft the manuscript; final
approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RX</td><td align="left" valign="top" rowspan="1" colspan="1">Conceived the study, participated in its
design and coordination, and helped to draft the manuscript; final
approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KL</td><td align="left" valign="top" rowspan="1" colspan="1">Conceived the study, participated in its
design and coordination, and helped to draft the manuscript; final
approval of the version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the 2<sup>nd</sup> Hospital of Bethune, Jilin
University, Changchun, Jilin, China.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ack><title>ACKNOWLEDGEMENT</title><p>We acknowledge the support by the Second Hospital of Jilin University within the
funding program. Open Access Publishing.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wijns</surname><given-names>W</given-names></name><name><surname>Kolh</surname><given-names>P</given-names></name><name><surname>Danchin</surname><given-names>N</given-names></name><name><surname>Di Mario</surname><given-names>C</given-names></name><name><surname>Falk</surname><given-names>V</given-names></name><name><surname>Folliguet</surname><given-names>T</given-names></name><etal/></person-group><article-title>Guidelines on myocardial revascularization: the task force on
myocardial revascularization of the European Society of Cardiology (ESC) and
the European Association for Cardio-Thoracic Surgery (EACTS)</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><issue>20</issue><fpage>2501</fpage><lpage>2555</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehq277</pub-id><pub-id pub-id-type="pmid">20802248</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hillis</surname><given-names>LD</given-names></name><name><surname>Smith</surname><given-names>PK</given-names></name><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Bittl</surname><given-names>JA</given-names></name><name><surname>Bridges</surname><given-names>CR</given-names></name><name><surname>Byrne</surname><given-names>JG</given-names></name><etal/></person-group><article-title>2011 ACCF/AHA guideline for coronary artery bypass graft surgery,
a report of the American College of Cardiology Foundation/American Heart
Association Task Force on practice guidelines. Developed in collaboration
with the American Association for Thoracic Surgery, Society of
Cardiovascular Anesthesiologists, and Society of Thoracic
Surgeons</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>58</volume><issue>24</issue><fpage>e123</fpage><lpage>e210</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2011.08.009</pub-id><pub-id pub-id-type="pmid">22070836</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>AD</given-names></name><name><surname>Roussin</surname><given-names>A</given-names></name><name><surname>Cartier</surname><given-names>R</given-names></name><name><surname>Chan</surname><given-names>WS</given-names></name><name><surname>Douketis</surname><given-names>JD</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><etal/></person-group><article-title>The use of antiplatelet therapy in the outpatient setting:
Canadian cardiovascular society guidelines</article-title><source>Can J Cardiol</source><year>2011</year><volume>27</volume><issue>Suppl A</issue><fpage>S1</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.cjca.2010.12.015</pub-id><pub-id pub-id-type="pmid">21640290</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karkouti</surname><given-names>K</given-names></name><name><surname>Wijeysundera</surname><given-names>DN</given-names></name><name><surname>Yau</surname><given-names>TM</given-names></name><name><surname>Beattie</surname><given-names>WS</given-names></name><name><surname>Abdelnaem</surname><given-names>E</given-names></name><name><surname>McCluskey</surname><given-names>SA</given-names></name><etal/></person-group><article-title>The independent association of massive blood loss with mortality
in cardiac surgery</article-title><source>Transfusion</source><year>2004</year><volume>44</volume><issue>10</issue><fpage>1453</fpage><lpage>1462</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2004.04144.x</pub-id><pub-id pub-id-type="pmid">15383018</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivacqua</surname><given-names>A</given-names></name><name><surname>Koch</surname><given-names>CG</given-names></name><name><surname>Yousuf</surname><given-names>AM</given-names></name><name><surname>Nowicki</surname><given-names>ER</given-names></name><name><surname>Houghtaling</surname><given-names>PL</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name><etal/></person-group><article-title>Morbidity of bleeding after cardiac surgery: is it blood
transfusion, reoperation for bleeding, or both?</article-title><source>Ann Thorac Surg</source><year>2011</year><volume>91</volume><issue>6</issue><fpage>1780</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2011.03.105</pub-id><pub-id pub-id-type="pmid">21619974</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eagle</surname><given-names>KA</given-names></name><name><surname>Guyton</surname><given-names>RA</given-names></name><name><surname>Davidoff</surname><given-names>R</given-names></name><name><surname>Edwards</surname><given-names>FH</given-names></name><name><surname>Ewy</surname><given-names>GA</given-names></name><name><surname>Gardner</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>ACC/AHA 2004 guideline update for coronary artery bypass graft
surgery: a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee to Update the 1999
Guidelines for Coronary Artery Bypass Graft Surgery)</article-title><source>Circulation</source><year>2004</year><volume>110</volume><issue>14</issue><fpage>e340</fpage><lpage>e437</lpage><pub-id pub-id-type="pmid">15466654</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitlock</surname><given-names>R</given-names></name><name><surname>Crowther</surname><given-names>MA</given-names></name><name><surname>Ng</surname><given-names>HJ</given-names></name></person-group><article-title>Bleeding in cardiac surgery: Its prevention and treatment-An
evidence-based review</article-title><source>Crit Care Clin.</source><year>2005</year><volume>21</volume><issue>3</issue><fpage>589</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1016/j.ccc.2005.04.003</pub-id><pub-id pub-id-type="pmid">15992674</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangano</surname><given-names>DT</given-names></name></person-group><article-title>Aspirin and mortality from coronary bypass
surgery</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><issue>17</issue><fpage>1309</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa020798</pub-id><pub-id pub-id-type="pmid">12397188</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dacey</surname><given-names>LJ</given-names></name><name><surname>Munoz</surname><given-names>JJ</given-names></name><name><surname>Johnson</surname><given-names>ER</given-names></name><name><surname>Leavitt</surname><given-names>BJ</given-names></name><name><surname>Maloney</surname><given-names>CT</given-names></name><name><surname>Morton</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Effect of preoperative aspirin use on mortality in coronary
artery bypass grafting patients</article-title><source>Ann Thorac Surg</source><year>2000</year><volume>70</volume><issue>6</issue><fpage>1986</fpage><lpage>1990</lpage><pub-id pub-id-type="doi">10.1016/S0003-4975(00)02133-0</pub-id><pub-id pub-id-type="pmid">11156107</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bybee</surname><given-names>KA</given-names></name><name><surname>Powell</surname><given-names>BD</given-names></name><name><surname>Valeti</surname><given-names>U</given-names></name><name><surname>Rosales</surname><given-names>AG</given-names></name><name><surname>Kopecky</surname><given-names>SL</given-names></name><name><surname>Mullany</surname><given-names>C</given-names></name><etal/></person-group><article-title>Preoperative aspirin therapy is associated with improved
postoperative outcomes in patients undergoing coronary artery bypass
grafting</article-title><source>Circulation</source><year>2005</year><volume>112</volume><issue>9 Suppl</issue><fpage>I286</fpage><lpage>I292</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.522805</pub-id><pub-id pub-id-type="pmid">16159833</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyke</surname><given-names>C</given-names></name><name><surname>Aronson</surname><given-names>S</given-names></name><name><surname>Dietrich</surname><given-names>W</given-names></name><name><surname>Hofmann</surname><given-names>A</given-names></name><name><surname>Karkouti</surname><given-names>K</given-names></name><name><surname>Levi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Universal definition of perioperative bleeding in adult cardiac
surgery</article-title><source>J Thorac Cardiovasc Surg</source><year>2014</year><volume>147</volume><issue>5</issue><fpage>1458</fpage><lpage>1463</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2013.10.070</pub-id><pub-id pub-id-type="pmid">24332097</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferraris</surname><given-names>VA</given-names></name><name><surname>Ferraris</surname><given-names>SP</given-names></name><name><surname>Joseph</surname><given-names>O</given-names></name><name><surname>Wehner</surname><given-names>P</given-names></name><name><surname>Mentzer Jr</surname><given-names>RM</given-names></name></person-group><article-title>Aspirin and postoperative bleeding after coronary artery bypass
grafting</article-title><source>Ann Surg</source><year>2002</year><volume>235</volume><issue>6</issue><fpage>820</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1097/00000658-200206000-00009</pub-id><pub-id pub-id-type="pmid">12035038</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesebro</surname><given-names>JH</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name><name><surname>Elveback</surname><given-names>LR</given-names></name><name><surname>Clements</surname><given-names>IP</given-names></name><name><surname>Smith</surname><given-names>HC</given-names></name><name><surname>Holmes Jr</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Effect of dipyridamole and aspirin on late vein-graft patency
after coronary bypass operations</article-title><source>N Engl J Med</source><year>1984</year><volume>310</volume><issue>4</issue><fpage>209</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1056/NEJM198401263100401</pub-id><pub-id pub-id-type="pmid">6361561</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesebro</surname><given-names>JH</given-names></name><name><surname>Clements</surname><given-names>IP</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name><name><surname>Elveback</surname><given-names>LR</given-names></name><name><surname>Smith</surname><given-names>HC</given-names></name><name><surname>Bardsley</surname><given-names>WT</given-names></name><etal/></person-group><article-title>A platelet-inhibitor-drug trial in coronary-artery bypass
operations: benefit of perioperative dipyridamole and aspirin therapy on
early postoperative vein-graft patency</article-title><source>N Engl J Med</source><year>1982</year><volume>307</volume><issue>2</issue><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1056/NEJM198207083070201</pub-id><pub-id pub-id-type="pmid">7045659</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alghamdi</surname><given-names>AA</given-names></name><name><surname>Moussa</surname><given-names>F</given-names></name><name><surname>Fremes</surname><given-names>SE</given-names></name></person-group><article-title>Does the use of preoperative aspirin increase the risk of
bleeding in patients undergoing coronary artery bypass grafting surgery?
Systematic review and meta-analysis</article-title><source>J Card Surg</source><year>2007</year><volume>22</volume><issue>3</issue><fpage>247</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8191.2007.00402.x</pub-id><pub-id pub-id-type="pmid">17488432</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>JCJ</given-names></name><name><surname>Whitlock</surname><given-names>R</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Eikelboom</surname><given-names>JW</given-names></name><name><surname>Thabane</surname><given-names>L</given-names></name><name><surname>Crowther</surname><given-names>MA</given-names></name><etal/></person-group><article-title>The effect of pre-operative aspirin on bleeding, transfusion,
myocardial infarction, and mortality in coronary artery bypass surgery: A
systematic review of randomized and observational studies</article-title><source>Eur Heart J</source><year>2008</year><volume>29</volume><issue>8</issue><fpage>1057</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehn104</pub-id><pub-id pub-id-type="pmid">18346962</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferraris</surname><given-names>VA</given-names></name><name><surname>Saha</surname><given-names>SP</given-names></name><name><surname>Oestreich</surname><given-names>JH</given-names></name><name><surname>Song</surname><given-names>HK</given-names></name><name><surname>Rosengart</surname><given-names>T</given-names></name><name><surname>Reece</surname><given-names>TB</given-names></name><etal/></person-group><article-title>2012 update to the society of thoracic surgeons guideline on use
of antiplatelet drugs in patients having cardiac and noncardiac
operations</article-title><source>Ann Thorac Surg</source><year>2012</year><volume>94</volume><issue>5</issue><fpage>1761</fpage><lpage>1781</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2012.07.086</pub-id><pub-id pub-id-type="pmid">23098967</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>CG</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Duncan</surname><given-names>AI</given-names></name><name><surname>Mihaljevic</surname><given-names>T</given-names></name><name><surname>Cosgrove</surname><given-names>DM</given-names></name><name><surname>Loop</surname><given-names>FD</given-names></name><etal/></person-group><article-title>Morbidity and mortality risk associated with red blood cell and
blood-component transfusion in isolated coronary artery bypass
grafting</article-title><source>Crit Care Med.</source><year>2006</year><volume>34</volume><issue>6</issue><fpage>1608</fpage><lpage>1616</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000217920.48559.D8</pub-id><pub-id pub-id-type="pmid">16607235</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surgenor</surname><given-names>SD</given-names></name><name><surname>Kramer</surname><given-names>RS</given-names></name><name><surname>Olmstead</surname><given-names>EM</given-names></name><name><surname>Ross</surname><given-names>CS</given-names></name><name><surname>Sellke</surname><given-names>FW</given-names></name><name><surname>Likosky</surname><given-names>DS</given-names></name><etal/></person-group><article-title>The association of perioperative red blood cell transfusions and
decreased long-term survival after cardiac surgery</article-title><source>Anesth Analg</source><year>2009</year><volume>108</volume><issue>6</issue><fpage>1741</fpage><lpage>1746</lpage><pub-id pub-id-type="doi">10.1213/ane.0b013e3181a2a696</pub-id><pub-id pub-id-type="pmid">19448195</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>GJ</given-names></name><name><surname>Reeves</surname><given-names>BC</given-names></name><name><surname>Rogers</surname><given-names>CA</given-names></name><name><surname>Rizvi</surname><given-names>SI</given-names></name><name><surname>Culliford</surname><given-names>L</given-names></name><name><surname>Angelini</surname><given-names>GD</given-names></name></person-group><article-title>Increased mortality, postoperative morbidity, and cost after red
blood cell transfusion in patients having cardiac surgery</article-title><source>Circulation</source><year>2007</year><volume>116</volume><issue>22</issue><fpage>2544</fpage><lpage>2552</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.698977</pub-id><pub-id pub-id-type="pmid">17998460</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surgenor</surname><given-names>SD</given-names></name><name><surname>DeFoe</surname><given-names>GR</given-names></name><name><surname>Fillinger</surname><given-names>MP</given-names></name><name><surname>Likosky</surname><given-names>DS</given-names></name><name><surname>Groom</surname><given-names>RC</given-names></name><name><surname>Clark</surname><given-names>C</given-names></name><etal/></person-group><article-title>Intraoperative red blood cell transfusion during coronary artery
bypass graft surgery increases the risk of postoperative low-output heart
failure</article-title><source>Circulation</source><year>2006</year><volume>114</volume><issue>1 Suppl</issue><fpage>I43</fpage><lpage>I48</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.001271</pub-id><pub-id pub-id-type="pmid">16820613</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiess</surname><given-names>BD</given-names></name></person-group><article-title>Transfusion of blood products affects outcome in cardiac
surgery</article-title><source>Semin Cardiothorac Vasc Anesth</source><year>2004</year><volume>8</volume><issue>4</issue><fpage>267</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1177/108925320400800402</pub-id><pub-id pub-id-type="pmid">15583789</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranucci</surname><given-names>M</given-names></name></person-group><article-title>Outcome measures and quality markers for perioperative blood loss
and transfusion in cardiac surgery</article-title><source>Can J Anaesth</source><year>2016</year><volume>63</volume><issue>2</issue><fpage>169</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1007/s12630-015-0515-8</pub-id><pub-id pub-id-type="pmid">26493314</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranucci</surname><given-names>M</given-names></name><name><surname>Baryshnikova</surname><given-names>E</given-names></name><name><surname>Castelvecchio</surname><given-names>S</given-names></name><name><surname>Pelissero</surname><given-names>G</given-names></name></person-group><article-title>Major bleeding, transfusions, and anemia: the deadly triad of
cardiac surgery</article-title><source>Ann Thorac Surg</source><year>2013</year><volume>96</volume><issue>2</issue><fpage>478</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2013.03.015</pub-id><pub-id pub-id-type="pmid">23673069</pub-id></element-citation></ref></ref-list></back></article>